lamifiban has been researched along with Syndrome in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, PW; Califf, RM; Christenson, RH; Fu, Y; Harrington, RA; Hasselblad, V; Kaul, P; Mahaffey, KW; Newby, LK; Ohman, EM; Topol, EJ; Van de Werf, F | 1 |
| Bhapkar, MV; Califf, RM; Davis, CG; Granger, CB; Harrington, RA; Hochman, JS; Moliterno, DJ; Newby, LK; Simes, RJ; Topol, EJ; Van de Werf, F | 1 |
| Adgey, AA | 1 |
| Ferguson, JJ; Lau, TK | 1 |
| Zidar, JP | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| SoRelle, R | 1 |
5 review(s) available for lamifiban and Syndrome
| Article | Year |
|---|---|
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1999 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
3 trial(s) available for lamifiban and Syndrome
| Article | Year |
|---|---|
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Assessment; Syndrome; Time Factors; Troponin T; Tyrosine | 2003 |
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
Topics: Acetates; Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Female; Heparin; Humans; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Partial Thromboplastin Time; Point-of-Care Systems; Syndrome; Tyrosine | 2002 |
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Titrimetry; Treatment Outcome; Tyrosine | 2002 |
1 other study(ies) available for lamifiban and Syndrome
| Article | Year |
|---|---|
Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.
Topics: Acetates; Acute Disease; Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Syndrome; Treatment Outcome; Tyrosine | 2002 |